Confirmed Speakers

Name:
Roderick L Beijersbergen PhD

Title:
Associate Professor and Director NKI Robotics and Screening Center

Research field:
Functional Genomics in Oncology

Education:
Biomedical Sciences, Leiden University
PhD Utrecht University


Former Professional experience:
AvL fellow The Netherlands Cancer Institute
Postdoctoral Fellow with Prof. RA Weinberg, Whitehead Institute for Biomedical Research, USA
Postdoctoral fellow with Prof. R Bernards, The Netherlands Cancer Institute
Research Associate, Harvard University, USA


Close window

Cedric Boularan is currently a Research Investigator at InvivoGen in Toulouse (France). He obtained his PhD in Cochin Institute (Paris), moved to a postdoctoral fellowship at the National Institutes of Health (Bethesda, MD) and then to Lifesearch, a biotech company. His research focused on in vitro and in vivo evaluation of mechanism regulating GPCR function for oncology, cardiology or immunology fields. His work has been published in major journals. He joined InvivoGen R&D department in 2015 to emphasize the preclinical proof of concept to use innate immune ligands (especially STING agonists) as onco-immuno-modulator.

Close window

Philipp Holliger is a Program Leader at the MRC Laboratory of Molecular Biology (LMB) in Cambridge, UK. Phil graduated from the Swiss Federal Institute of Technology (ETH) Zürich with Steven A Benner. He then moved to Cambridge for a Ph.D. and a postdoctoral fellowship with Sir Gregory Winter. In 2000, he joined the faculty at the LMB where he was tenured in 2005.

His research spans the fields of chemical biology, synthetic biology and in vitro evolution. His work has been published in major journals (e.g. Nature, Science, Cell etc.) and has led to numerous patents. His recent work, describing a range of novel synthetic genetic polymers (XNAs) was featured in Scientific American’s 10 World Changing Ideas (2012). He is a member of the European Molecular Biology Organization (EMBO) and a consultant to several successful biotech companies including Cambridge Antibody Technology / Medimmune, Solexa / Illumina, Domantis and GSK.

Close window

After obtaining his Ph.D. in Organic Chemistry from the University of Antwerp in 2003, Tim joined the Medicinal chemistry department of Tibotec, a Johnson & Johnson affiliate. In 2010, the Tibotec team moved to Janssen Pharmaceutica in Beerse, Belgium. Currently, he is Scientific Director at Janssen and holds the position of Head of Medicinal Chemistry, Infectious Diseases. His main research focus is the identification of new small molecule inhibitors -including novel nucleoside derivatives- useful for the treatment of viral diseases.

Close window

Henrik Möbitz is currently group leader and Senior Research Investigator, Global Discovery Chemistry at Novartis. In this role, he has lead medicinal chemistry projects and external collaborations. Prior to this, he studied enzyme mechanisms by use of biochemistry (PhD at Albert-Ludwigs-Universität Freiburg in 2003) and simulation (Postdoctoral Fellow at UC Santa Barbara). Recent research projects target epigenetic methyl transferases, helicases, kinases and the MAPK pathway in particular, by integrating structure based design and data analysis.

Close window

Prof. Dr. Georg Sczakiel, Director of the Institute of Molecular Medicine ,University of Luebeck, Germany

Research areas: Antisense nucleic acids, oligonucleotide-based drugs, RNA-RNA interactions, delivery, intracellular trafficking, RNA-based non-invasive diagnostics, urine RNA

Diploma in Chemistry (University of Freiburg), Ph.D. in Molecular Biology (Max-Planck-Institute, Heidelberg), Habilitation in Theoretical Medicine (German Cancer Research Center, Heidelberg), Post-Doc in Tsukuba and Tokyo (Japan), Project leader, Steinbeis Transfer Center for Genome Informatics (Heidelberg)

Close window